ArticleBMC cardiovascular disorders2026
Serial cardiac MR assessment and histopathological evaluation of doxorubicin-induced cardiomyopathy in a miniature swine model.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveDoxorubicin-induced cardiomyopathy remains challenging to detect at an early stage. This study aims to assess cardiac MR changes and their pathological correlates in a swine model of doxorubicin-induced cardiomyopathy.
methodsMiniature pigs received repeated intravenous doxorubicin administration and underwent serial cardiac MR examinations from baseline to 32 weeks. Left ventricular function, global strain, and T2 relaxation time were assessed longitudinally. Histological and ultrastructural analyses were performed at predefined time points to evaluate myocardial injury.
resultsLVEF remained relatively preserved during doxorubicin administration and showed only a non-significant declining trend during follow-up. LVGLS showed a non-significant decreasing trend during the treatment (weeks 0-8, P = 0.068) and stabilized during the follow-up period (weeks 8-32, P = 0.35); GCS demonstrated deterioration (week 4: P = 0.006; week 32: P < 0.001); while GRS exhibited significant impairment, with maximal reduction at week 20 (β=-12.87, P = 0.04) that persisted through week 32 (P = 0.001). T2 mapping analysis showed significant elevation during active treatment (χ²=10.5, P = 0.033), followed by partial recovery by the final follow-up (week 32: 36.74 ± 2.80 ms, P = 0.020). Histopathological evaluation demonstrated mitochondrial swelling/vacuolization during treatment, with substantial resolution by week 32. However, persistent abnormalities in myocardial fiber architecture were observed at the study endpoint.
conclusionsIn this miniature swine model, T2 prolongation during doxorubicin treatment was temporally associated with mitochondrial-related ultrastructural alterations and may reflect potentially reversible components of myocardial injury. Persistent strain abnormalities despite T2 normalization suggest incomplete structural recovery, mainly reflecting ultrastructural alterations rather than fibrotic progression. Combined T2 mapping and strain assessment may provide complementary information for characterizing doxorubicin-related myocardial injury in preclinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.